CAR T cell therapy has become a new way to treat many types of cancer, and Israel has made a lot of progress in this area. Israeli medical centres have been on the cutting edge of CAR T cell therapy study and development, giving patients with blood cancers that haven’t responded to other treatments hope. Israeli scientists have helped create and make CAR T cells, which has improved their effectiveness and safety. CAR T cell kurapa has been used successfully on patients at Israeli hospitals like Sheba Medical Centre, Tel Aviv hospital, and Hadassah Medical Centre. This has led to amazing remissions and higher mortality rates. Israel is still very important to the progress of CAR T cell treatment, which gives cancer patients all over the world new hope.
CAR T cell therapy, rudzi rutsva rwe immunotherapy iyo iri kuita kuputika kukuru mumunda wekuchengetedza cancer, muenzaniso wakanaka. Zvipatara zvine mukurumbira nenzvimbo dzekufunda muIsrael dzanga dziri pamberi mukugadzira nekushandisa kurapa kutsva uku, zvichipa tariro kune vanhu vane mhando dzakasiyana dzegomarara. CAR T-Cell kurapa muIsrael yave kuwanikwa muzvipatara zvakawanda.
The Sheba Medical Center ndiyo imwe yenzvimbo dzakanakisa muIsrael kuwana CAR T cell kurapwa. Yakamisa iyo Center for Cellular immunotherapy, iyo inotarisira kugadzira uye kupa kunze kwemunhu CAR T cell kurapa. Chikwata cheShebha chenyanzvi chafambira mberi zvinoshamisa mukubatsira vanhu kanzura yeropa kufanana neleukemia uye lymphoma. Varwere vanobva kumativi ose enyika vanoda kurapwa kwepamusoro vanouya kwavari nekuda kweruzivo rwavo uye zvivakwa zvemazuva ano.
Another important place is the Hadassah Medical Centre in Jerusalem, which has been doing a lot of study into CAR T cell therapy. Their main goal has been to help kids with acute lymphoblastic leukaemia (ALL) that has come back or doesn’t respond to treatment. The success nyaya from Hadassah have given hope to families going through hard times, as CAR T cell therapy could be a lifeline for those with few treatment choices.
Mumakore achangopfuura, kurapwa kweCAR T cell kwakafambira mberi zvakanyanya muIsrael. Vatsvagiri vanga vachitsvaga nzira dzekuita kuti marapirwo ashande zvirinani uye kubatsira vanhu vazhinji. Imwe yeiyi kushandiswa kwemasero eCAR T ane zvinangwa zviviri zvakasiyana. Nekutevera akawanda maantigen kamwechete, nzira iyi ine chinangwa chekuita kuti kurapa kubudirire uye kuderedza njodzi yekupukunyuka kweantigen, ndipo apo maseru egomarara anodzivirira kuzivikanwa neCAR T masero.
Zvakare, masayendisiti eIsrael anga achitsvaga nzira nyowani dzekurapa mamota akasimba, anga akaoma kurapa kupfuura zvirwere zvehematological munguva yakapfuura. Vatsvagiri vepaTel Aviv Sourasky Medical Center vanga vachiyedza masero eCAR T akachinjwa kuti agadzire mamwe mamorekuru anogona kuita nani pakuuraya mamota akasimba. Mibairo yekutanga iri kutaridzika zvakanaka, izvo zvinopa vanhu tariro yekuti CAR T cell therapy inogona kunge iri nhanho hombe mukurapa mapundu akasimba.
CAR T cell therapy yakashandura mabatirwo egomarara, ichipa varwere sarudzo itsva uye tariro itsva. MuIsrael, zvipatara zvakanakisa nenzvimbo dzekufunda dzinoramba dzichimanikidza miganhu yekurapa uku, kuyedza kuita kuti ishande zvirinani uye kubatsira vanhu vazhinji. Sezvo tsvagiridzo ichienda kumberi, kurapwa kweCAR T cell kungangove kwakakosha muIsrael nepasirese mukurwisa cancer.
Mari yeCAR T-Cell kurapwa muIsrael yakadzikira zvakanyanya pane iri munyika dzakaita seUS, UK, Australia, Japan, Korea neSingapore. CAR T-Cell kurapa muIsrael inogona kungodhura madhora makumi manomwe neshanu-75 USD. Israel ine yakaenzana kuwanikwa kweCAR T cell therapy. Israel yakamisa nzvimbo nezvipatara zvinorapa mhando dzakasiyana dzegomarara neCAR-T cell kurapwa. Masangano aya anga achiita kurapwa kwerudzi urwu kwenguva yakareba uye achiwana zvivakwa uye maturusi avanoda. Pakusarudza kwekuwana CAR-T cell therapy, zvakakosha kufunga nezve kuwanikwa.
Kana zvigadzirwa zveCAR T-cell zvinogadzirwa mukati-mumba, zvine mwero wakafanana wekubudirira sekutengesa CAR yakagadzirwa ne pharma, pasina zvikanganiso zvekugadzira. Kugadzirisa hurongwa hwese pa-saiti zvinoreva kuti nguva kubva paleukapheresis kuenda kuCAR manejimendi inogona kudzikiswa kusvika pamazuva gumi. Izvi zvinoreva kuti murwere haafanire kuenda kuburikidza nebridging therapy, iyo yakabatana nemhedzisiro iri nani. Muchidimbu nguva yose yekurapa inoderedza chete kusvika kumazuva makumi matatu kana ichienzaniswa nemazuva 10-30 kune dzimwe nyika.
Israel inozivikanwa nezvidzidzo zvayo zvekurapa zvakanakisa uye mazano matsva. Nyika yaita budiriro yakakosha kune immunotherapy, kusanganisira CAR-T cell therapy. Vanachiremba nevakoti veIsrael vanowanzova vekutanga kugadzira nekushandisa marapirwo matsva, vachiita chokwadi chekuti varwere vavo vanowana rubatsiro rwepamusoro.
Tumira marepoti ako ekurapwa ku info@cancerfax.com kana WhatsApp kwavari + 1-213 789-56-55 kana Fonera +91 96 1588 1588. Tumira mishumo inotevera kuti uwane maonero uye fungidziro:
1) Pfupiso yezvokurapa
2) Mishumo yeropa yazvino
3) Biopsy
4) Latest PET Scan
5) Bone marrow biopsy (Kana iripo)
6) Chero mimwe mishumo yakakodzera uye scans
Kana timu yedu yangogamuchira marepoti ako ekurapa, tinoaongorora tozvitumira kuzvipatara zviri kuita CAR T-Cell therapy nerudzi irworwo rwegomarara nechimaka. Isu tinotumira mishumo kune ane hanya nyanzvi uye tinowana maonero ake. Isu tinowanawo fungidziro kubva kuchipatara pakurapwa kwakakwana. Izvi zvinokubatsira mukuronga nguva yese yekurapa.
Kana ukangofunga kushanyira kurapwa, tinoronga tsamba yevhiza yekurapa uye mamwe magwaro anodiwa kubva kuchipatara. Isu tinobatsirawo uye nekukutungamira mukunyorera vhiza yekurapa kumumiriri weIsrael. Kana vhiza yagadzirira isu tinobatsira uye nekukutungamira mukugadzirira matikiti ekufamba uye endege. Isu tinorongawo hotera yako uye imba yevaenzi, kana ichidikanwa muIsrael. Pakusvika muguta rekurapa mumiriri wedu achakugamuchirai panhandare yendege.
Mumiriri wedu acharonga kugadzwa kwachiremba uye kuzadzisa zvinodiwa zvekunyoresa iwe. Achakubatsirawo nekupinzwa muchipatara uye nerumwe rubatsiro rwenzvimbo nerutsigiro rwunodiwa. Kana kurapwa kwapera isu ticharonga kuti iwe utevere kubvunzana nachiremba anorapa.
CAR T-cell therapy, iyo inoitwa kuSheba Hospital muTel Aviv, Israel, idanho guru rekurapa gomarara. Inopa vanhu vane mamwe marudzi egomarara reropa tariro. MuchiHebheru, Shebha Hospital inonzi Tel HaShomer. Ndicho chipatara chikuru muIsrael uye mutungamiri munharaunda yeCAR T-cell therapy.
Chipatara cheSheba chine maturusi epamusoro-soro uye matekinoroji ekubatsira neCAR T-cell therapy. Chipatara ichi chine mayunitsi akakosha akamisikidzwa nehunyanzvi hwezvino kugadzira maseru. Izvi zvinova nechokwadi chokuti T masero akagadziridzwa eCAR-akagadziridzwa ega ega anogadzirwa nokukurumidza uye zvisina ngozi. Zvakare, chikwata chevanachiremba navanamukoti vepaSheba Hospital vane ruzivo rwakanyanya rwekuita miedzo yekiriniki uye kudzidza CAR T-cell therapy, iyo inobatsira munda uyu kuti urambe uchiita zviri nani.
Iyo Tel Aviv Sourasky Medical Center (Ichilov Hospital) inzvimbo yaunogona kuwana mhando nyowani yekurapa inonzi mota T-cell therapy. Mukurapa kutsva uku, masero eT emurwere anochinjirwa gene kuti akwanise kuziva nekurwisa maseru egomarara. Muviri wemurwere unobva wazadzwa nemasero aya akachinjwa murabhoritari. Ikoko, vanogona kuwana nekuuraya masero ekenza. Chirongwa cheCar T-cell therapy paTel Aviv Sourasky Medical Center chinofambiswa nechikwata chevanachiremba uye nyanzvi dzeimmunotherapy vane ruzivo rwakawanda. Varwere vane marudzi akasiyana egomarara vanogona kuve netariro nesarudzo iyi yemhando yepamusoro yekurapa, iyo inovapa yakasarudzika uye inoshanda nzira yekurwisa chirwere ichi.
The Hadassah Medical Centre in Jerusalem is at the heart of a new way to treat cancer called Car T-cell therapy. Car T-cell therapy changes and activates T cells so they can recognise and fight cancer cells. It does this by using the power of the patient’s own immune system. The skilled group of doctors and experts at Hadassah work together to provide this cutting-edge therapy. Hadassah Medical Centre gives people with different kinds of cancer hope and better outcomes with its cutting-edge equipment and dedication to new ideas. Car T-cell therapy at Hadassah is a shining example of progress in the field of oncology. It gives patients choices for personalized and targeted treatment.
Tora nyanzvi yechipiri maonero paCAR T-Cell therapy infusion kubva kune akanakisa CAR T-Cell kurapa nyanzvi muIsrael.
CAR T-Cell kurapa
Nhoroondo: Arnon Nagler, akashanda kwemakore akawanda semutungamiriri wezvose zviri zviviri Division of Hematology uye Bone Marrow Transplantation uye Cord Ropa Bank paChaim Sheba Medical Center, uye Purofesa weMishonga paThe Tel Aviv University, Israel.
Pediatric Hematology
Nhoroondo: Prof. Amos Toren ndiye Mutungamiriri wePediatric Hemato-Oncology uye BMT Division, akavimbiswa muPediatrics, General Hematology uye Pediatric Hemato-Oncology. Akashanda seMusoro wechikamu cheHematology paSackler Chikoro cheMishonga Tel-Aviv University kwematamu maviri.
CAR T-Cell kurapa
Nhoroondo: Prof. Dina Ben-Yehuda, mukuru weHadassah Medical Organisation's Department of Hematology, akanzi Dean weHadassah-Hebrew University Faculty of Medicine– mukadzi wekutanga kuva nechinzvimbo.
Mutengo weCAR T-Cell kurapwa muIsrael unotanga kubva pamadhora makumi manomwe neshanu emadhora depending upon the brand of CAR T chosen. For local home grown CAR T therapy cost will be around \$ 80,000 USD whereas for therapies like Kymeriah and Breyanzi cost may go up to \$ 470,000 USD. Car T-cell therapy costs can vary in Israel based on a number of things, such as the medical centre, the type of cancer being treated, and the health of the patient. Car T-cell therapy is a complicated and highly specialized treatment that includes changing genes and giving each patient their own care. Because of this, it is an expensive procedure. In general, the costs of Car T-cell therapy include the process of genetic engineering, hospitalisation, fees for medical staff, and tracking after the treatment. Patients should talk to their healthcare providers and insurance companies to find out what the costs might be and what kinds of financial help or insurance benefits are available.
Chimeric antigen receptor T-cell therapy, inowanzozivikanwa seCAR T-cell therapy, ivhu-inoputsa immunotherapy iyo yakashandura zvachose nzira iyo kenza inorapwa. Inopa varwere vane mamwe magomarara tariro yaimboonekwa seisingarapike kana kuti ine nzira shoma dzekurapa.
Kurapa uku kunosanganisira kushandisa masero emuviri emuviri wemurwere-kunyanya, T masero-uye kuachinja-chinja kuvandudza kugona kwavo kuona nekuparadza maseru egomarara. Kuti aite izvi, masero eT anopihwa chimeric antigen receptor (CAR), iyo inovapa kugona kunanga mamwe mapuroteni, kana maantigen, pamusoro pemasero egomarara.
Masero eT kubva kumurwere anotanga kubviswa, uye anobva agadziriswa genetically kuratidza CAR. Murabhoritari, masero akachinjwa aya anowanzwa kuti abudise huwandu hwakati wandei hwemasero eCAR T, anozodzoserwa muropa remurwere.
Pavanenge vari mukati memuviri, masero eCAR T anowana masero ekenza anoratidza antigen inodiwa, anonamatira paari, uye anokonzera simba rekudzivirira zvirwere. Masero eCAR T akabatiswa anowedzera uye anoita kurwisa kwakanangana nemasero egomarara, achiauraya.
Kana ichishandiswa kurapa mamwe maronda eropa senge acute lymphoblastic leukemia (ALL) uye chaiwo mafomu e lymphoma, CAR T-cell therapy yakaratidza mhedzisiro. Yakaburitsa mhinduro dzinozivikanwa uye mune vamwe varwere, kunyangwe kuregererwa kwenguva refu.
CAR T-cell therapy, zvisinei, inzira yakaoma uye yakasarudzika yekurapa inogona kuve nenjodzi nemhedzisiro yakaipa. Cytokine release syndrome (CRS), yakapararira immunological reaction iyo inogona kukonzera zviratidzo-sefuruwenza uye, mumamiriro ezvinhu akaipisisa, kutadza kwenhengo, kunogona kuitika kune vamwe vanhu. Pakave zvakare nemishumo yezvinokonzeresa neurological yakashata, zvisinei iyo inowanzorapika.
Zvisinei nematambudziko aya, CAR T-cell therapy ibudiriro huru mukurwisa gomarara uye inoratidza kugona kukuru kweramangwana. Zvidzidzo zvazvino zvinonangana nekusimudzira kushanda kwayo uye kuchengetedza chimiro pamwe nekuwedzera mashandisiro ayo kune akasiyana marudzi egomarara. CAR T-cell therapy ine kugona kushandura chiso chekurapa cancer uye kupa varwere kwese kwese tariro itsva nekumwe kufambira mberi.
T masero anotorwa muropa rako uchishandisa chubhu inoiswa mutsinga yeruoko. Izvi zvinotora maawa mashoma.
Masero eT anotakurwa kuenda kunzvimbo uko anogadziridzwa genetic modified kuti ave masero eCAR-T. Vhiki mbiri kana nhatu dzinopfuura mukati meizvi.
Masero eCAR-T anopinzwazve muropa rako kuburikidza nedrip. Izvi zvinoda maawa akawanda.
Masero eCAR-T anotarisa uye anobvisa masero egomarara mumuviri wese. Mushure mekugamuchira CAR-T kurapwa, iwe unozotariswa zvakanyanya.
Only patients with adult B-cell non-lymphoma Hodgkin’s or pediatric acute lymphoblastic leukemia who have already tried two unsuccessful conventional therapies can currently use CAR T-cell therapy products that have received FDA approval. However, CAR T-cell therapy is now being tested in clinical studies as a first or second-line treatment for adult lymphoma and pediatric acute lymphoblastic leukemia. Recently, some of the studies have shown remarkable successes in cases of solid tumors too like glioblastoma, gliomas, liver cancer, lung cancer, GI cancer, pancreatic cancer and nomumukanwa kenza.
Izvi zvinomiririra kufambira mberi kwakakosha mukutarisira kweleukemia uye B-cell lymphoma. Uyezve, inopa tariro kune avo vaimbofanotaurwa kuti vaizogara mwedzi mitanhatu chete. Zvino zvataona nzira dzekuramba uye nekugadzira mamwe matekiniki ekuzvirwisa, ramangwana rinoita serinonyanya kuvimbisa.
Bata nevatapi vedu vane ruzivo rwakanyanya pano pa CancerFax kubvunzurudzwa kwemahara kugadzira chirongwa chekuchengetedza chakakodzera chezvinodiwa zvehutano hwako. Ndokumbira utumire marepoti ako ekurapa ku info@cancerfax.com kana WhatsApp kune + 1 213 789 56 55.
The main benefit is that CAR T-cell therapy only requires a single infusion and often only requires two weeks of inpatient care. Patients with non-Hodgkin lymphoma uye leukemia yevana vachangobva kuongororwa, kune rumwe rutivi, vanowanzoda chemotherapy kweinenge mwedzi mitanhatu kana kupfuura.
Zvakanakira zveCAR T-cell therapy, inova iri mushonga mhenyu, inogona kuramba iripo kwemakore mazhinji. Kana uye kana kudzokazve kukaitika, maseru anozokwanisa kuona uye kunanga maseru egomarara nekuti anogona kurarama mumuviri kwenguva yakareba.
Kunyange zvazvo ruzivo ruchiri kusimukira, 42% yevarwere vakuru ve lymphoma vakawana CD19 CAR T-cell kurapwa vakanga vachiri mukuregererwa mushure memwedzi gumi nemishanu. Uye mushure memwedzi mitanhatu, zvikamu zviviri muzvitatu zvevarwere vane acute lymphoblastic leukemia vakanga vachiri mukuregererwa. Nehurombo, varwere ava vaive nemamota ane hasha asina kurapwa nenzira yechinyakare yekuchengeta.
Varwere vari pakati peMakore matatu kusvika kuMakore makumi manomwe vakaedzwa neCAR T-Cell kurapwa kwemhando dzakasiyana dzegomarara reropa uye zvakaonekwa kuti zvinoshanda zvakanyanya. Nzvimbo zhinji dzakati budiriro inopfuura 3%. Munhu anonyatsokwanisa kumirira CAR T-cell therapy panguva ino mwana ane acute lymphoblastic leukemia kana munhu mukuru ane B-cell lymphoma yakakomba anga atova nemitsetse miviri yekurapa kusingashandi.
Gore ra2017 risati rapera, pakanga pasina mwero wakagamuchirwa wekutarisira varwere vanga vatopfuura nemitsetse miviri yekurapa vasina kuwana kuregererwa. Mushonga chete wakatenderwa neFDA kusvika parizvino waratidza kubatsira zvakanyanya kuvarwere ava ndeyeCAR T-cell therapy.
CAR T-cell therapy has been very effective in treating some types of blood cancer, like acute lymphoblastic leukaemia (ALL) and isiri-Hodgkin lymphoma. In clinical trials, the response rates have been very good, and a lot of patients have gone into full remission. In some cases, people who had tried every other medicine had long-lasting remissions or even possible cures.
Chimwe chezvinhu zvakanakisa nezveCAR T-sero kurapwa ndechekuti inonangana nemasero akakodzera. Iwo maCAR receptors akawedzerwa kumasero eT anogona kuwana chaiwo mamaki pamasero egomarara. Izvi zvinoita kuti zvikwanise kupa kurapa kwakanangwa. Iyi nzira yakanangwa inokuvadza maseru ane hutano zvishoma sezvinobvira uye inodzikisa njodzi yemhedzisiro inouya nemishonga yechinyakare senge chemotherapy.
Asi zvakakosha kuyeuka kuti CAR T-cell therapy ichiri nzvimbo itsva ichiri kuchinja. Vatsvagiri uye vanachiremba vari kushanda nesimba kuti vagadzirise matambudziko akaita semutengo wakakwira, mukana wemhedzisiro yakakomba, uye chokwadi chekuti inongoshanda kune mamwe marudzi egomarara.
Pakupedzisira, CAR T-cell therapy yakaratidza kuva nzira yakabudirira zvikuru yekurapa mamwe marudzi egomarara reropa. Kunyangwe iri nzira inovimbisa uye ine simba, kudzidza kwakawanda uye miedzo yekiriniki inodiwa kuivandudza nekutsvaga nzira nyowani dzekuishandisa. CAR T-cell therapy inogona kushandura marapirwo egomarara uye kuita kuti zvinhu zvirinani kuvanhu pasi rose kana ikaramba ichipora.
1. Varwere vane CD19 + B-cell Lymphoma (Angangoita 2 pamberi musanganiswa chemotherapy maitiro)
2. Kuva ane makore matatu kusvika makumi manomwe nemashanu ekuberekwa
3. ECOG zvibodzwa ≤2
4. Vakadzi vane mikana yekuzvara vana vanofanira kuongororwa weti kuti vane pamuviri uye voonekwa kuti havana kubatwa here vasati varapwa. Vose varwere vanobvumirana kushandisa nzira dzakavimbika dzekudzivirira pamuviri panguva yekuedzwa uye kusvika pakutevera kwenguva yekupedzisira.
1. Intracranial neBP kana kufenda
2. Kutadza kufema
3. Yakaparadzirwa intravascular coagulation
4. Hematosepsis kana Utachiona husingadzoreki hunoshanda
5. Chirwere cheshuga chisingadzoreki.
B-cell precursor acute lymphoblastic leukemia, yakadzokororwa kana refractory diffuse hombe B-cell lymphoma
Yese mhinduro mwero (CR):> 90%
Chinangwa: CD19
Price: $ 475,000
Nguva yekubvumidza: Nyamavhuvhu 30, 2017
Kudzokororwa kana kudzoreredza kuparadzira hombe B-cell lymphoma, yakadzokororwa kana refractory follicular cell lymphoma.
Non-Hodgkin's lymphoma Yakazara mhinduro mwero (CR): 51%
Chinangwa: CD19
Price: $ 373,000
Nguva yekubvumidza: 2017 Gumiguru 18
Kudzokororwa kana refractory diffuse hombe B-cell lymphoma
Mantle cell lymphoma Yese yekupindura mwero (CR): 67%
Chinangwa: CD19
Price: $ 373,000
Nguva Yakabvumirwa: Gumiguru 18, 2017
Kudzokororwa kana refractory diffuse hombe B-cell lymphoma
Yese yekupindura mwero (CR): 54%
Chinangwa: CD19
Price: $ 410,300
Nguva Yakabvumirwa: Gumiguru 18, 2017
Relapsed or Refractory siyana-siyana Myeloma
Yese yekupindura mwero: 28%
Chinangwa: CD19
Price: $ 419,500
Yakabvumirwa: Gumiguru 18, 2017
Pazasi pane mamwe emhedzisiro yeCAR T-Cell therapy.
Zvakakosha kuyeuka kuti havasi murwere wese achava nemigumisiro iyi, uye kuti nhanho yemunhu wega wega inosiyana. Kuti uderedze uye uderedze zvinokonzeresa zvinokonzeresa izvi, timu yekurapa inoongorora varwere nguva isati yasvika, panguva, uye mushure meCAR T-cell therapy.
Tarisa pazasi nguva yakazara inodiwa kuti upedze iyo CAR T-Cell kurapwa maitiro. Kunyangwe nguva yakatarwa inotsamira zvakanyanya kureba kwerabhoritari kubva kuchipatara yakagadzira iyo CAR.
Yese nguva yakatarwa: 10-12 Mavhiki
Nhanganyaya Munzvimbo inogara ichishanduka yekurapa oncological, vesainzi vanoramba vachitsvaga zvinangwa zvisina kujairika zvinogona kukwidziridza kushanda kwekupindira uku vachideredza zvinokonzeresa zvisingadiwe.
Human-based CAR T-cell therapy inosandura kurapwa kwegomarara nekugadzirisa magene masero emuviri emurwere kuti anange nekuparadza maseru egomarara. Nekushandisa simba rekudzivirira kwemuviri, marapirwo aya anopa marapiro ane simba uye emunhu ane mukana wekuregererwa kwenguva refu mumhando dzakasiyana dzegomarara.
Cytokine Release Syndrome (CRS) is immune system reaction inowanzo kukonzerwa nemamwe marapirwo senge immunotherapy kana CAR-T cell therapy. Zvinosanganisira kuburitswa kwakanyanya kwemacytokines, zvichikonzera zviratidzo kubva pafivha uye kuneta kusvika kune zvinogona kuuraya hupenyu sekukuvadzwa kwenhengo. Kutungamira kunoda kunyatsotarisisa uye nzira dzekupindira.
Paramedics inobata basa rakakosha mukubudirira kweCAR T-cell therapy nekuona kuchengetwa kwemurwere pasina musono panguva yese yekurapa. Vanopa rubatsiro rwakakosha panguva yekufambisa, kutarisa zviratidzo zvinokosha zvevarwere, uye kupa rubatsiro rwechimbichimbi kana matambudziko amuka. Kupindura kwavo nekukurumidza uye kutarisirwa kwehunyanzvi kunobatsira mukuchengetedzeka kwese uye kushanda kwekurapa, kufambisa shanduko yakapfava pakati pezvirongwa zvehutano uye kuvandudza mhedzisiro yevarwere munzvimbo yakaoma yemhando yepamusoro cellular therapies.
Mumunda we oncology, kubuda kwerapi yakanangwa kwakashandura mamiriro ekurapa egomarara repamusoro. Kusiyana neakajairwa chemotherapy, iyo inonangana nekukurumidza kupatsanura maseru, kurapa kwakanangwa kunovavarira kurwisa cancer maseru uku uchideredza kukuvadzwa kwemaseru akajairwa. Iyi chaiyo nzira inoitwa kuti igoneke nekuona chaiwo mamolecular shanduko kana biomarkers ayo akasiyana nekenza maseru. Nekunzwisisa iwo mamolecular profiles emamota, oncologists vanogona kugadzirisa marapirwo ekurapa anoshanda zvakanyanya uye asina muchetura. Muchikamu chino, tinoongorora misimboti, mashandisirwo, uye kufambira mberi kweanonangwa kurapa mugomarara repamusoro.
Nhanganyaya Immunotherapy yave nzira inokatyamadza mukurapwa kwegomarara, kunyanya kurapwa kwegomarara repamusoro iro rakaratidza kushanda kushoma nemishonga yakajairwa. Izvi